(PRWEB) May 24, 2017
RegenLab USA LLC (“RegenLab”) has filed a patent infringement lawsuit in the U.S. District Court for the Southern District of New York, Case No. 17-cv-03845 (S.D.N.Y.) (filed May 22, 2017). The named defendants are Raj Kanodia, M.D., Garden City Dermatology, P.C., and Trifecta Health Medical P.C., who commercially promote a product called “Eclipse PRP” on their websites. RegenLab may seek to add additional defendants to the Complaint as they are identified.
RegenLab is a leading innovator of medical products for the preparation of platelet rich plasma, which it markets under the world-famous REGENLAB® brand. Platelet rich plasma contains a high concentration of blood platelets and proteins that promote natural wound healing. RegenLab developed a new and extremely effective way to enhance platelet rich plasma production that is patented in U.S. Pat. No. 8,529,957 (“the ‘957 patent”). Over the course of many years, RegenLab has developed a substantial patent portfolio, including a number of pending patent applications in the same family as the ‘957 patent. RegenLab’s products for preparing platelet rich plasma include its RegenKit® products, which are marked with the ‘957 patent in accordance with 35 U.S.C. § 287.
The above-mentioned case concerns alleged infringement of the ‘957 patent for the Eclipse PRP product that is manufactured by Estar Technologies Ltd. (“Estar”) and distributed by Eclipse Aesthetics LLC (“Eclipse”). This product is also marketed under the brand names “Tropocells” and “Healeon PRP.” The case alleges that Estar/Eclipse knew about RegenLab’s patent rights and copied RegenLab’s products that incorporate the technology of the ‘957 patent to develop these infringing products. RegenLab recently filed suit against Estar and Eclipse for their alleged infringement, Case No. 16-cv-08771 (ALC) (S.D.N.Y.) (filed Nov. 11, 2016).
Raj Kanodia, M.D., Garden City Dermatology, P.C., and Trifecta Health Medical P.C. are believed to be customers of Estar/Eclipse who use, sell, and offer for sale the Eclipse PRP product. Such actions make them liable for direct infringement, contributory infringement, and inducing others to infringe RegenLab’s patent rights. RegenLab seeks treble damages resulting from the use and sale of the infringing products, attorneys’ fees and costs, and a permanent injunction to preclude continued use and sale.
RegenLab remains committed to providing products of the highest quality and safety, as well as protecting customers from illegitimate products through enforcement of its intellectual property rights. RegenLab’s affiliate in Switzerland, Regen Lab SA, has filed multiple patent infringement lawsuits against Estar in Europe, alleging infringement of European patents related to the ‘957 patent.
Additional information about RegenLab can be found at http://www.RegenLabUSA.com.